Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546637 · ClinicalTrials.gov registry record · Phase 3
Fesoterodine "add-on" Male Overactive Bladder Study
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 947
- Enrollment target
NCT00546637: Completed Phase 3 study, sponsored by Pfizer.
NCT00546637 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 947 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00546637, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 947 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Primary Outcome
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS Scale \>= 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Interventions
- DRUG Placebo
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 947 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
What the finished NCT00546637 record still lists
NCT00546637 is an interventional study that assigns participants to a tested intervention. The registered 947 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00546637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00546637 about?
NCT00546637 is a clinical study titled "Fesoterodine "add-on" Male Overactive Bladder Study". To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
What is the current status of trial NCT00546637?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 947 participants. The study started on 2007-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00546637?
The interventions under investigation include: Placebo (DRUG), Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT00546637?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00546637's enrollment target sits among peer trials
947 334th of 2000 higher than 1,667 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia